Morning Glory Sciences– Author –
-
[August 2025 Update] The Frontline of the Obesity Drug Race: Lilly’s Setback, Emerging Biotechs, Big Pharma Strategies, and Chugai’s Moves
Introduction As of August 2025, the obesity drug race is undergoing major shifts. Eli Lilly and Novo Nordisk remain dominant, but biotech challengers and Big Pharma entries are redrawing the competitive map. This article reviews the late... -
The p53–MDM2 Axis Protects the Blood-Brain and Blood-Retina Barriers: From Aging and Genetic Vulnerability to Cancer Brain Metastasis Risk
Introduction The blood-brain barrier (BBB) and blood-retina barrier (BRB) are essential for maintaining the homeostasis of the central nervous system (CNS). The blood-brain barrier (BBB) and blood-retina barrier (BRB) are essential for m... -
Proteins Are “More Stable” Than We Thought: Mega-scale Experiments and Interpretable Models Refresh Design Rules
Even with solved structures, folding thermodynamics (ΔG) has long been hard to see. Even with solved structures, folding thermodynamics (ΔG) has long been hard to see. Recent work closes this gap with mega-scale measurements and a simple... -
[Beginner-Friendly | Bispecific Antibody Drugs] Vol.6: Evolution of Bispecific Antibody Technologies — A Historical Overview of Engineering Breakthroughs
In this final deep-dive of our beginner-friendly bispecific antibody series, we explore the historical trajectory of bispecific antibody (BsAb) technology. In this final deep-dive of our beginner-friendly bispecific antibody series, we e... -
Why Gene & Cell Therapies Stall at the FDA (2024–2025): What Recent CRLs Reveal about CMC, Inspections, and Trial Design
In July 2025, the FDA began publishing past Complete Response Letters (CRLs). In July 2025, the FDA began publishing past Complete Response Letters (CRLs). Triangulating those releases with company disclosures and primary reporting shows... -
Beginner-Friendly｜Bispecific Antibody Drug Series Vol. 5: Latest Advances and 1-Year Approval Roundup
In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. In this final volume, we summarize th... -
Beginner-Friendly｜Bispecific Antibody Drug: Pharmacological Differences Based on Modalities Vol.4
Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significantly depending on the structural modality. Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significa... -
Oncology Drug Approval News Flash: FDA Grants Accelerated Approval to Zongertinib (Hernexeos) for HER2 TKD-Mutated NSCLC
On August 8, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for adults with unresectable or metastatic non-squamo... -
Oncology Drug Approval News Flash: FDA Grants Accelerated Approval to Dordaviprone (Modeyso) for H3 K27M-Mutant Diffuse Midline Glioma
On August 6, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals), a protease activator, for adult and pediatric patients (≥1 year) with progressive H3 K27M-mutant... -
Beginner-Friendly Series｜Bispecific Antibody Drug Vol.3：Strategic Considerations in Selecting Targets for Bispecific Antibody Drugs
In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we delve into the crucial question: “Which targets should be selec In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we... -
[Beginner’s Guide to Bispecific Antibody Drugs] Vol.2 – Comparing Structural Designs and Their Impact on Therapeutic Efficacy
In this second installment of our series on bispecific antibody drugs, we delve into the diverse structural formats that define the field. In this second installment of our series on bispecific antibody drugs, we delve into the diverse s... -
Beginner-Friendly｜What Are Bispecific Antibody Drugs? A Thorough Introduction (Part 1)
Introduction: Why Are Bispecific Antibody Drugs Gaining Attention? In recent years, bispecific antibody drugs (BsAbs) have garnered increasing attention in the treatment of cancer, autoimmune diseases, and infectious diseases. In recent ... -
🧬 Unraveling Insulin Resistance and Type 2 Diabetes with Personalized Molecular Maps: The Power of Proteomics and Genomics
Why do some people develop diabetes while others with similar lifestyles don’t?The answer may lie in your molecular fingerprint. This article summariz Why do some people develop diabetes while others with similar lifestyles don’t?The ans... -
Arsenic Life and the Cost of Scientific Integrity: A 15-Year Retraction from Science
■ Introduction In July 2025, the prestigious journal Science officially retracted a paper it had published in 2010, claiming the discovery of a bacterium that could substitute arsenic for phosphorus in its DNA. In July 2025, the prestigi... -
Pharma/Biotech News | Layoff Trends in the U.S. Biotech Sector 2025: Industry Reset or Prelude to a New Wave?
Fierce Biotech's "Layoff Tracker 2025" has captured a wave of downsizing across the U.S. biotech landscape in the first half of 2025. This article bre Fierce Biotech's "Layoff Tracker 2025" has captured a wave of downsizing across the U.... -
Beginner-Friendly in vivo CAR-T Series | Part 8
Global Strategies Shaping the Future of in vivo CAR-T Development Throughout this series, we have explored the cutting-edge developments of in vivo CAR-T therapy in an accessible way for beginners. Throughout this series, we have explore... -
Beginner-Friendly in vivo CAR-T Series｜Part 7
Key Figures Shaping the Future of in vivo CAR-T This series aims to provide a clear and accessible overview of the latest advancements in in vivo CAR-T therapies, especially for beginners. This series aims to provide a clear and accessib... -
In vivo CAR-T’s Convergence Phase: 4 Emerging Technologies That Could Reshape Cell Therapy
In vivo CAR-T therapy has rapidly emerged as a promising next-generation cancer treatment. In vivo CAR-T therapy has rapidly emerged as a promising next-generation cancer treatment. However, realizing its full potential requires overcomi... -
In vivo CAR-T’s First Wave of Clinical Trials: Reading the Players, Targets, and Frontiers
In previous installments, we've explored the fundamentals of CAR-T, the features of the in vivo model, gene delivery strategies, target antigens, and intracellular signaling. In previous installments, we've explored the fundamentals of C... -
[Introductory In vivo CAR-T Series #4] Deep Dive into CAR Structure: The Latest in Co-stimulation and Signal Engineering
For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. In pa...
